| Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study AR Mato, NN Shah, W Jurczak, CY Cheah, JM Pagel, JA Woyach, ... The Lancet 397 (10277), 892-901, 2021 | 444 | 2021 |
| Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial NN Shah, BD Johnson, D Schneider, F Zhu, A Szabo, CA Keever-Taylor, ... Nature Medicine 26 (10), 1569-1575, 2020 | 427 | 2020 |
| Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial M Jagasia, MA Perales, MA Schroeder, H Ali, NN Shah, YB Chen, S Fazal, ... Blood, The Journal of the American Society of Hematology 135 (20), 1739-1749, 2020 | 269 | 2020 |
| Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study C Cutler, SJ Lee, S Arai, M Rotta, B Zoghi, A Lazaryan, A Ramakrishnan, ... Blood, The Journal of the American Society of Hematology 138 (22), 2278-2289, 2021 | 237 | 2021 |
| Optimizing chimeric antigen receptor T-cell therapy for adults with acute lymphoblastic leukemia NV Frey, PA Shaw, EO Hexner, E Pequignot, S Gill, SM Luger, ... Journal of Clinical Oncology 38 (5), 415-422, 2020 | 233 | 2020 |
| Multi Targeted CAR-T Cell Therapies for B-cell Malignancies N Shah, T Maatman, PN Hari, B Johnson Frontiers in Oncology 9, 146, 2019 | 198 | 2019 |
| Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States AR Mato, M Thompson, JN Allan, DM Brander, JM Pagel, CS Ujjani, ... Haematologica 103 (9), 1511, 2018 | 181 | 2018 |
| National Marrow Donor Program–sponsored multicenter, phase II trial of HLA-mismatched unrelated donor bone marrow transplantation using post-transplant cyclophosphamide BE Shaw, AM Jimenez-Jimenez, LJ Burns, BR Logan, F Khimani, ... Journal of Clinical Oncology 39 (18), 1971-1982, 2021 | 161 | 2021 |
| Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome MR Hines, TE Knight, KO McNerney, MB Leick, T Jain, S Ahmed, ... Transplantation and Cellular Therapy 29 (7), 438. e1-438. e16, 2023 | 151 | 2023 |
| Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia AR Mato, JA Woyach, JR Brown, P Ghia, K Patel, TA Eyre, T Munir, ... New England Journal of Medicine 389 (1), 33-44, 2023 | 138 | 2023 |
| Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center F Zhu, N Shah, H Xu, D Schneider, R Orentas, B Dropulic, P Hari, ... Cytotherapy 20 (3), 394-406, 2018 | 119 | 2018 |
| Efficacy, toxicity, and infectious complications in ruxolitinib-treated patients with corticosteroid-refractory graft-versus-host disease after hematopoietic cell transplantation S Abedin, E McKenna, S Chhabra, M Pasquini, NN Shah, J Jerkins, ... Biology of Blood and Marrow Transplantation 25 (8), 1689-1694, 2019 | 106 | 2019 |
| Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1–2 study T Siddiqi, DG Maloney, SS Kenderian, DM Brander, K Dorritie, ... The Lancet 402 (10402), 641-654, 2023 | 102 | 2023 |
| R‐CHOP versus dose‐adjusted R‐EPOCH in frontline management of primary mediastinal B‐cell lymphoma: a multi‐centre analysis NN Shah, A Szabo, SF Huntington, N Epperla, N Reddy, S Ganguly, ... British journal of haematology 180 (4), 534-544, 2018 | 102 | 2018 |
| Tumor lysis, adverse events, and dose adjustments in 297 venetoclax-treated CLL patients in routine clinical practice LE Roeker, CP Fox, TA Eyre, DM Brander, JN Allan, SJ Schuster, ... Clinical Cancer Research 25 (14), 4264-4270, 2019 | 90 | 2019 |
| Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents LE Roeker, P Dreger, JR Brown, OB Lahoud, TA Eyre, DM Brander, ... Blood Advances 4 (16), 3977-3989, 2020 | 81 | 2020 |
| Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure SM Smith, J Godfrey, KW Ahn, A DiGilio, S Ahmed, V Agrawal, ... Cancer 124 (12), 2541-2551, 2018 | 81 | 2018 |
| A novel autologous CAR-T therapy, YTB323, with preserved T-cell stemness shows enhanced CAR T-cell efficacy in preclinical and early clinical development MJ Dickinson, P Barba, U Jäger, NN Shah, D Blaise, J Briones, L Shune, ... Cancer discovery 13 (9), 1982-1997, 2023 | 74 | 2023 |
| Outcomes of front‐line ibrutinib treated CLL patients excluded from landmark clinical trial AR Mato, LE Roeker, JN Allan, JM Pagel, DM Brander, BT Hill, ... American journal of hematology 93 (11), 1394-1401, 2018 | 72 | 2018 |
| Safety and Effectiveness of Vedolizumab in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease: A Retrospective Record Review Y Fløisand, VL Lazarevic, J Maertens, J Mattsson, NN Shah, P Zachée, ... Biology of Blood and Marrow Transplantation 25 (4), 720-727, 2019 | 71 | 2019 |
